Page last updated: 2024-10-25

citalopram and Disease Exacerbation

citalopram has been researched along with Disease Exacerbation in 14 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"Suicidal ideation was more likely to occur early in citalopram treatment, with few subjects showing emergence or worsening occurring after 6 weeks of treatment."9.22Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. ( Bloch, MH; Coughlin, CG; Jakubovski, E, 2016)
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI."9.17Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013)
" The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)."7.76Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010)
"Suicidal ideation was more likely to occur early in citalopram treatment, with few subjects showing emergence or worsening occurring after 6 weeks of treatment."5.22Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. ( Bloch, MH; Coughlin, CG; Jakubovski, E, 2016)
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI."5.17Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013)
" The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)."3.76Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010)
"To test the hypothesis that the selective serotonin reuptake inhibitor (SSRI) citalopram would down-regulate human immunodeficiency virus (HIV) infectivity and that the greatest effects would be seen in people with depression."3.76Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. ( Benton, T; Blume, J; Douglas, SD; Dubé, B; Evans, DL; Gettes, DR; Lynch, K; Metzger, DS; Ping Lai, J; Tustin, NB, 2010)
"Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2."2.76Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. ( Calugi, S; Cassano, GB; Fagiolini, A; Frank, E; Miniati, M; Rucci, P; Scocco, P, 2011)
"The manifestations of daytime somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1)."1.36Excessive daytime somnolence in spinocerebellar ataxia type 1. ( Cunnington, D; Dang, D, 2010)
"Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6."1.35Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. ( Alpert, JE; Fava, M; Fleck, J; Gilmer, WS; Gollan, JK; Howland, RH; Miyahara, S; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2008)
"Hypersexuality in Alzheimer's disease (AD) has been rarely investigated."1.35Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's9 (64.29)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Audley, GG1
Frankenfeld, P1
Dlamini, S1
Raubenheimer, P1
Hoare, J1
Cairncross, L1
Van den Berg, R1
Gule, MV1
Calligaro, G1
Kobayashi, M1
Kwak, MJ1
Aguilar, D1
Goyal, P1
Holmes, HM1
Deshmukh, AA1
Aparasu, RR1
Kelley, ME1
Dunlop, BW1
Nemeroff, CB1
Lori, A1
Carrillo-Roa, T1
Binder, EB1
Kutner, MH1
Rivera, VA1
Craighead, WE1
Mayberg, HS1
Jiang, W1
Velazquez, EJ1
Kuchibhatla, M1
Samad, Z1
Boyle, SH1
Kuhn, C1
Becker, RC1
Ortel, TL1
Williams, RB1
Rogers, JG1
O'Connor, C1
Choe, YM1
Kim, KW1
Jhoo, JH1
Ryu, SH1
Seo, EH1
Sohn, BK1
Byun, MS1
Bak, JH1
Lee, JM1
Yun, HJ1
Han, MI1
Woo, JI1
Lee, DY1
Coughlin, CG1
Jakubovski, E1
Bloch, MH1
Gilmer, WS2
Gollan, JK1
Wisniewski, SR3
Howland, RH1
Trivedi, MH3
Miyahara, S1
Fleck, J1
Thase, ME1
Alpert, JE1
Nierenberg, AA2
Warden, D2
Fava, M3
Rush, AJ3
Tosto, G1
Talarico, G1
Lenzi, GL1
Bruno, G1
Dang, D1
Cunnington, D1
Sacre, S1
Medghalchi, M1
Gregory, B1
Brennan, F1
Williams, R1
Benton, T1
Lynch, K1
Dubé, B1
Gettes, DR1
Tustin, NB1
Ping Lai, J1
Metzger, DS1
Blume, J1
Douglas, SD1
Evans, DL1
Rucci, P1
Frank, E1
Scocco, P1
Calugi, S1
Miniati, M1
Fagiolini, A1
Cassano, GB1
Zisook, S1
Sung, SC1
Haley, CL1
Chan, HN1
Balasubramani, GK1
Gaynes, BN2
Hollon, SD1
Spencer, D1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847]Phase 4127 participants (Actual)Interventional2006-09-30Completed
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878]Phase 390 participants (Actual)Interventional2022-12-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

5HTT, Serotonin Transporter Protein

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6

Interventionfmol/mg (Mean)
Escitalopram139.7
Placebo160.4

Beck Depression Inventory

The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionunits on a scale (Mean)
Escitalopram7.4
Placebo7.0

Cook-Medley Hostility (Ho) Hostile Affect Sub-scale

hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram1.6
Placebo1.8

Cook-Medley Hostility (Ho) Scale

Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram9.9
Placebo10.3

Exercise Stressed-induced Myocardial Ischemia (ESIMI)

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionpercentage of change (Number)
Escitalopram45.8
Placebo52.5

Mental Stress Induced Change in Heart Rate

"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks

Interventionbeats/minute (Mean)
Escitalopram6.34
Placebo9.1

Mental Stress Induced Change of Diastolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram11.4
Placebo12.2

Mental Stress Induced Change of Systolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram19.3
Placebo23.6

Perceived Stress Scale

Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram21.4
Placebo21.8

Percentage of Participants With Adverse Events

(NCT00574847)
Timeframe: Baseline to week 6

Interventionpercentage of participants (Number)
Escitalopram71.9
Placebo44.4

Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6

Interventionpercentage of participants (Number)
Escitalopram34.2
Placebo17.5

Percentage of Participants With Overall Mental Stress-induced Myocardial Ischemia (MSIMI)

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6

Interventionpercentage of participants (Number)
Escitalopram66.1
Placebo83.9

Platelet Serotonin Binding Affinity Kd_100

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

InterventionnM (Mean)
Escitalopram4202.4
Placebo210.1

Spielberger State-Trait Anxiety Inventory Scales (STAI)

STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

,
Interventionunits on a scale (Mean)
TraitState
Escitalopram31.227.9
Placebo32.029.5

Reviews

1 review available for citalopram and Disease Exacerbation

ArticleYear
The STAR*D study: treating depression in the real world.
    Cleveland Clinic journal of medicine, 2008, Volume: 75, Issue:1

    Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Disease Progres

2008

Trials

5 trials available for citalopram and Disease Exacerbation

ArticleYear
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
    JAMA, 2013, May-22, Volume: 309, Issue:20

    Topics: Aged; Citalopram; Coronary Disease; Disease Progression; Double-Blind Method; Electrocardiography; E

2013
Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
    International journal of geriatric psychiatry, 2016, Volume: 31, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Brain; Citalop

2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:10

    Topics: Adult; Citalopram; Depressive Disorder, Major; Disease Progression; Female; Follow-Up Studies; Human

2016
Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
    Depression and anxiety, 2011, Volume: 28, Issue:4

    Topics: Adult; Anxiety Disorders; Benzodiazepines; Citalopram; Combined Modality Therapy; Comorbidity; Depre

2011
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Psychological medicine, 2012, Volume: 42, Issue:6

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Chronic Dis

2012

Other Studies

8 other studies available for citalopram and Disease Exacerbation

ArticleYear
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, 10-08, Volume: 110, Issue:12

    Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling;

2020
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016.
    The American journal of cardiology, 2021, 08-01, Volume: 152

    Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi

2021
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
    Depression and anxiety, 2018, Volume: 35, Issue:10

    Topics: Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cognitive Behavio

2018
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:8

    Topics: Adult; Chronic Disease; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistic

2008
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29, Issue:4

    Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo

2008
Excessive daytime somnolence in spinocerebellar ataxia type 1.
    Journal of the neurological sciences, 2010, Mar-15, Volume: 290, Issue:1-2

    Topics: Activities of Daily Living; Amantadine; Ataxin-1; Ataxins; Brain Stem; Cerebellum; Citalopram; Dextr

2010
Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured;

2010
Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.
    Psychosomatic medicine, 2010, Volume: 72, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; CD8-Positive T-Lymphocytes; Cell Line; Cells, Cultured; C

2010